Targets › TGF-BETA
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on TGF-BETA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Pirfenidone Anti-fibrotic agent with anti-inflammatory properties | TNF, TGF-BETA | Phase 2 | To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma | Dec 2026 |
To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma (1)
mixed (1)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.